8-K
filed November 18, 2022, 6:59 PM ET
ticker DGX
CIK 0001022079
leadership
confidence high
sentiment neutral
materiality 0.30
Quest Diagnostics appoints four executive officers to severance plan; amends by-laws
QUEST DIAGNOSTICS INC
- Four executives appointed as executive officers and Schedule B participants in severance plan: Mark Delaney, Mark Gardner, Karthik Kuppusamy, Patrick Plewman (effective Nov 16, 2022).
- Board amended by-laws on Nov 14, 2022 regarding director nominations, proxy solicitations, and compliance with Rule 14a-19.
- Schedule B participants receive 1x salary + 1x bonus pre-CIC; 2x salary + bonus post-CIC, plus benefits.
- By-law amendments are ministerial, clarifying, and conforming changes.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Patrick T. Plewman was appointed as Senior Vice President for Diagnostic Services at QUEST DIAGNOSTICS INC.
- Action
- appointed
- Role
- Senior Vice President for Diagnostic Services
Exact text from the filing
On November 16, 2022, Mark E. Delaney, Senior Vice President and Chief Commercial Officer; Mark A. Gardner, Senior Vice President, Molecular Genomics and Oncology; Karthik Kuppusamy, Senior Vice President, Clinical Solutions and Patrick T. Plewman, Senior Vice President for Diagnostic Services, became executive officers of Quest Diagnostics Incorporated (the "Company) and became Schedule B participants in the Company's Executive Officer Severance Plan (the "Plan").
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Karthik Kuppusamy was appointed as Senior Vice President, Clinical Solutions at QUEST DIAGNOSTICS INC.
- Action
- appointed
- Role
- Senior Vice President, Clinical Solutions
Exact text from the filing
On November 16, 2022, Mark E. Delaney, Senior Vice President and Chief Commercial Officer; Mark A. Gardner, Senior Vice President, Molecular Genomics and Oncology; Karthik Kuppusamy, Senior Vice President, Clinical Solutions and Patrick T. Plewman, Senior Vice President for Diagnostic Services, became executive officers of Quest Diagnostics Incorporated (the "Company) and became Schedule B participants in the Company's Executive Officer Severance Plan (the "Plan").
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Mark E. Delaney was appointed as Senior Vice President and Chief Commercial Officer at QUEST DIAGNOSTICS INC.
- Action
- appointed
- Role
- Senior Vice President and Chief Commercial Officer
Exact text from the filing
On November 16, 2022, Mark E. Delaney, Senior Vice President and Chief Commercial Officer; Mark A. Gardner, Senior Vice President, Molecular Genomics and Oncology; Karthik Kuppusamy, Senior Vice President, Clinical Solutions and Patrick T. Plewman, Senior Vice President for Diagnostic Services, became executive officers of Quest Diagnostics Incorporated (the "Company) and became Schedule B participants in the Company's Executive Officer Severance Plan (the "Plan").
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Mark A. Gardner was appointed as Senior Vice President, Molecular Genomics and Oncology at QUEST DIAGNOSTICS INC.
- Action
- appointed
- Role
- Senior Vice President, Molecular Genomics and Oncology
Exact text from the filing
On November 16, 2022, Mark E. Delaney, Senior Vice President and Chief Commercial Officer; Mark A. Gardner, Senior Vice President, Molecular Genomics and Oncology; Karthik Kuppusamy, Senior Vice President, Clinical Solutions and Patrick T. Plewman, Senior Vice President for Diagnostic Services, became executive officers of Quest Diagnostics Incorporated (the "Company) and became Schedule B participants in the Company's Executive Officer Severance Plan (the "Plan").
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
QUEST DIAGNOSTICS INC: Amended and restated By-Laws to revise Sections 1.05, 1.06 and 1.07 regarding director nominations and proxy solicitations, including compliance with Rule 14a-19, and incorporate ministerial, clarifying and conforming changes (effective 2022-11-14).
- Change
- bylaw amendment
- Effective
- 2022-11-14
Exact text from the filing
On November 14, 2022, the Board of Directors (the “Board”) of the Company amended and restated the Company's By-Laws (the "By-Laws"). The amendments (a) revise Sections 1.05, 1.06 and 1.07 with respect to nominations of directors and solicitations of proxies, including compliance with Rule 14a-19 under the Securities Exchange Act of 1934, as amended, and (b) incorporate ministerial, clarifying and conforming changes.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.